KLRS
Kalaris Therapeutics, Inc.
2.70$
-5.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Kalaris Therapeutics, Inc. (KLRS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -11 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.9 | -6.4 | -8.9 | -11 | -11 | -18 | -21 | -19 | -23 | -36 | -28 | -46 | -29 | -35 | -32 | -32 | -27 | -34 | -4.1 | -4.5 | -4.0 | -4.3 | -7.9 | -7.4 | -15 | -11 | -9.3 | -13 | -11 | -45 | |
| – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.8 | 0.4 | 0.2 | 1.1 | 0.5 | – | 3.6 | – | – | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | 0.3 | 0.3 | 0.3 | 0.4 | 0.6 | 0.6 | 0.3 | 0.6 | 0.6 | 2.2 | |
| 1.1 | 0.6 | -0.6 | -1.8 | 0.0 | 1.6 | -0.8 | 3.4 | 4.3 | -1.7 | 13 | -14 | 4.4 | -3.9 | -2.7 | -0.8 | 8.5 | -3.1 | -0.8 | -2.1 | -0.2 | 1.2 | -1.1 | 2.3 | -1.8 | 0.0 | 2.9 | -1.1 | -0.1 | 1.6 | |
| 0.2 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.3 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.2 | |
| -100 | 0.0 | 35 | 14 | 25 | -210 | 1.9 | 65 | 80 | 55 | -14 | -55 | -0.5 | -39 | 14 | 42 | 38 | -67 | – | – | – | – | – | – | – | -35 | 15 | -50 | 20 | -50 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 5.0 | 0.0 | 10.0 | 7.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 121 | – | – | – | – | 292 | -0.4 | – | – | 0.2 | 0.1 | – | 0.2 | 126 | 0.3 | – | 70 | – | 6.9 | 6.6 | 5.0 | 0.0 | 7.6 | 107 | 2.3 | 0.0 | 50 | 0.1 | 0.0 | 50 | |
| – | – | 61 | 3.3 | 14 | 64 | -20 | 46 | 57 | 18 | -42 | -101 | -29 | 53 | -18 | 9.6 | 81 | -101 | 2.7 | 2.1 | 1.0 | 12 | -0.3 | 100 | -13 | -46 | 56 | -64 | 8.7 | -45 | |
| -3.1 | -6.4 | -9.0 | -11 | -11 | -18 | -21 | -19 | -23 | -36 | -28 | -46 | -29 | -35 | -32 | -32 | -27 | -34 | -4.1 | -4.5 | -4.0 | -4.3 | -7.9 | -7.4 | -15 | -12 | -9.3 | -13 | -11 | -46 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.